title: [Intraocular application of bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks].
abstract: Angioid streaks are the typical ophthalmological manifestation of the systemic disease pseudoxanthoma elasiticum. Fundoscopy reveals angioid streaks as irregular dark brownish lines radiating from the area around the optic disc. Choroidal neovascularization (CNV) is the major cause of severe visual loss in patients with angioid streaks. Argon-laser treatment of CNV secondary to angioid streaks shows poor results. Photodynamic therapy (PDT) with verteporfin does not seem to be an effective treatment for achieving stabilization of visual acuity and lesion size in CNV secondary to angioid streaks. Results after a combination of the intravitreal application of triamcinolone with PDT did not show the expected benefit. In the era of promising new intravitreal treatments for patients suffering from age-related macular degeneration, it is interesting to observe this effect of angiogenesis inhibitors (bevacizumab, ranibizumab, pegaptanib) in patients with neovascilarization secondary to angioid streaks. In our case, we observed a deterioration in visual acuity and leakage of the CNV after treatment with PDT alone. However, after the intravitreal injection of bevacizumab, we observed an improvement in vision, and the area of neovascularization changed into a fibrotic scar. A controlled study with long-term results is needed to definitively evaluate this kind of treatment.
authors.affiliation: Augenabteilung am St. Franziskus Hospital, Münster, Deutschland. Kpl-auge@muenster.de
authors.forename: A
authors.initials: A
authors.lastname: Lommatzsch
authors.forename: G
authors.initials: G
authors.lastname: Spital
authors.forename: M
authors.initials: M
authors.lastname: Trieschmann
authors.forename: D
authors.initials: D
authors.lastname: Pauleikhoff
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000793:Angioid Streaks / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab